

Lupus: Lupkynis

Member Information								
1. L	ast Name:		2. First Name:					
3. 1	Frillium ID #:	Name: 2. First Name: ium ID #: 4. Date of Birth: 5. Gender:						
Prescr	riber Information							
1. F	1. Prescriber Name: 2. NPI #:							
3. F	Requestor Name (Nurse/Office Staff): City: State: Zip: _							
4. N	Mailing Address:			City: ₋		State:	Zip:	
5. F	Phone #:		Ext	Fax #	t:			
	nformation							
1. Dr	rug Name:	2	2. Strength: 3.			. Quantity Per 30 Days:		
4. Le	ngth of Therapy (in Days):	☐ up to 30 Days	☐ 60 Days	☐ 90 Days	☐ 120 Days ☐] 180 Days □	365 Days	
Clinica	al Information							
Initia	al authorization (answer a	uestions 1-12)						
	ial authorization (answer questions 1-12)							
	Does the member have a diagnosis of active systemic lupus nephritis? Yes No No Does the member have International Society of Nephrology/Renal Pathology Society (ISN/RPS) biopsy-proven							
	active Class III or IV Lupus Nephritis alone or in combination with Class V Lupus Nephritis? Yes No							
	What is the member's urine protein to creatinine (UPCR) ratio?							
	Is the member age 18 or older? Yes No							
	Does the member have hypersensitivity to any component of the medication? Yes No							
	Is the medication being administered with strong CYP3A4 inhibitors? (ex. Ketoconazole, itraconazole,							
	clarithromycin) \square Yes \square No							
	Does the member have severe hepatic impairment? Yes No							
	Is the member concomitantly receiving background immunosuppressive therapy? (with the exception of							
	cyclophosphamide) \square Yes \square No							
	Please list the member's baseline blood pressure							
10. F	Please list the member's baseline glomerular filtration rate (eGFR)							
	. Will renal function (eGFR) be assessed at regular intervals? □ Yes □ No							
	Is the medication being prescribed by or in consultation with a rheumatologist? Yes No							
Forr	ro outhorization (anguar a	uestions 12 15)						
	for re-authorization (answer questions 13-15) 3. Does the member continue to meet above criteria? (questions 1-12) Yes No							
	Does the member show disease improvement and/or stabilization or improvement in the slope of decline?							
	☐ Yes ☐ No	ase improvement	and/or stabili	zation or imp		, slope of decili	iiC:	
		d any treatment-re	stricting adv	erse effects?	(ex hypertensi	on neurotoxici	ties	
	5. Has the member experienced any treatment-restricting adverse effects? (ex. hypertension, neurotoxicities, hyperkalemia) Yes No							
	**Please attach current progress notes documenting disease status and clinical response to the medicine.							
Sign	nature of Prescriber:				Date:			

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

Trillium – Lupus – Lupkynis Orig. 7/2024